Flipper, thank you very much and they certainly are points worth repeating. I hope over this quarter or so NWBO is more transparent about it's existing compassionate use programme. If the results can't be discussed in detail, for reasons of ticking off the FDA, I hope they'd atleast update us on where the revenues from the programme are booked, and what flow they are seeing in terms of number of cases being treated monthly. Apart from the clinic in Israel, this would also include the "Specials" programme at King's College Hospital in London. (for those of us who are not familiar with this, I'd encourage reading John's correspondence on cancercompass with a man from Egypt, Nabil, who was looking at treatment options for his mother, who was diagnosed with GBM).
Though Linda didn't raise the possibility of compassionate use approval in Germany yesterday (and I'm glad she didn't. I'd rather expectations are not raised on a regulatory decision that is entirely out of NWBO's control), since she did bring up the existing compassionate use programme, albeit indirectly, I would expect more light to be shone on this area that NWBO has been all cloak-and-dagger about for the past 5 years.
News 
Market Data 
Discover 
